Clinical <i>CYP2D6</i> Genotyping to Personalize Adjuvant Tamoxifen Treatment in ER-Positive Breast Cancer Patients: Current Status of a Controversy

Clinical <i>CYP2D6</i> Genotyping to Personalize Adjuvant Tamoxifen Treatment in ER-Positive Breast Cancer Patients: Current Status of a Controversy

Tamoxifen is a major option for adjuvant endocrine treatment in estrogen receptor (ER) positive breast cancer patients. The conversion of the prodrug tamoxifen into the most active metabolite endoxifen is mainly catalyzed by the enzyme cytochrome P450 2D6 (CYP2D6). Genetic variation in the <i>...

Full description

Bibliographic Details
Main Authors: Tessa A. M. Mulder, Mirjam de With, Marzia del Re, Romano Danesi, Ron H. J. Mathijssen, Ron H. N. van Schaik
Format: Article
Language:English
Published: MDPI AG 2021-02-01
Series:Cancers
Subjects:
tamoxifen
Pharmacogenetics
PGx
CYP2D6
Cytochrome P450 2D6
genotyping
Online Access:https://www.mdpi.com/2072-6694/13/4/771

Internet

https://www.mdpi.com/2072-6694/13/4/771

Similar Items